KOSDAQBiotech & Pharma246720

Asta

₩6,070 0.00%2026-11-18 close
Market Cap
₩99.4B
Turnover
₩0
Volume
0 shares
Shares out.
16.4M
PER
—
PBR
—
EPS
-₩292
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses persist as trading halt and audit disclaimer weigh

Asta posted operating losses every year from 2022 through 2025, its shares have been halted since March 24, 2026 after an audit disclaimer on fiscal 2025, and a change-of-largest-shareholder contract was released in October 2026.

  1. 1

    Trading halt: an audit disclaimer on the fiscal 2025 accounts, caused by a limit on audit scope, triggered a delisting ground on March 24, 2026, and the exchange set the improvement period to April 10, 2027.

  2. 2

    Annual results: 2025 sales were KRW 2.59 billion, down 22.7% year on year, and the operating loss narrowed to KRW 2.59 billion from KRW 4.02 billion in 2024. The operating margin was -99.8%.

  3. 3

    Quarterly flow: operating losses have run for five consecutive quarters from Q3 2025 to Q3 2026, and net losses attributable to controlling shareholders total KRW 4.6 billion over the last four quarters.

  4. 4

    Ownership change: a share transfer agreement signed on February 10, 2026 (contract value KRW 32.8 billion) was released on October 16, 2026 after the buyer notified termination.

  5. 5

    Business trend: per WiseReport data as of September 6, 2026, first-half 2026 standalone sales rose 113.0% while the operating loss widened 22.2%.

02

Business structure

Asta is a mass-spectrometry-based diagnostics company founded in 2006 and listed on KOSDAQ in March 2017. Its core business is MALDI-TOF mass spectrometry instruments and related consumables, led by the MicroIDSys and IDSys LT/RT microbial identification systems for clinical use.

The company says it has built a database of more than 5,000 bacterial species. Its lineup also includes NosIDSys for cancer and rare-disease diagnostics, LDI-TOF instruments for industrial uses such as OLED analysis, disposable MALDI plates and sample pretreatment systems.

According to WiseReport's company profile, products and merchandise account for 94.83 percent of sales.

By product, as of December 2025, the Data Generation Unit and diagnostic systems were 58.20 percent domestic and 41.80 percent export, sample pretreatment systems were 45.08 percent domestic and 54.92 percent export, and service revenue was 95.12 percent domestic and 4.88 percent export.

Customers include hospitals, testing centers, food hygiene and livestock quarantine agencies, and the company also cites bioterrorism prevention use.

On September 30, 2025, Asta disclosed a demo supply of diagnostic equipment to a Saudi medical research institute, and it is pursuing Middle East expansion through a Saudi joint venture and technology licensing.

In April 2026 it signed a mass spectrometer supply contract with Kangwon National University worth KRW 401 million, equal to 11.95 percent of sales. Microbial identification by mass spectrometry is cited for shortening result times compared with culture or molecular methods. The company had 41 employees as of June 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.1B-₩500M−47.5%
2025Q4₩800M-₩500M−63.0%
2026Q1₩500M-₩1.1B−240.8%
2026Q2₩1.2B-₩800M−71.7%
2026Q3₩400M-₩1B−231.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3.3B-₩2.8B-₩2.8B−83.1%−38.7%51.1%
2023₩3.1B-₩2.7B—−86.9%—57.3%
2024₩3.4B-₩4B-₩3.9B−119.8%−93.2%106.4%
2025₩2.6B-₩2.6B-₩3.3B−99.8%−35.8%67.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On the disclosed annual figures, sales fell from KRW 3.35 billion in 2022 to KRW 3.13 billion in 2023 (down 6.3 percent year on year), recovered to KRW 3.35 billion in 2024 (up 7.1 percent), and dropped to KRW 2.59 billion in 2025 (down 22.7 percent). Among 2022 to 2025, 2024 was the largest year and 2025 the smallest.

Operating losses were KRW 2.78 billion in 2022, KRW 2.72 billion in 2023 (loss narrowed), KRW 4.02 billion in 2024 (loss widened) and KRW 2.59 billion in 2025 (loss narrowed), and the company has been loss-making in each of the four years from 2022 to 2025.

In 2025 the loss narrowed even as sales fell, and the operating margin improved from -119.8 percent in 2024 to -99.8 percent in 2025.

In its standalone disclosure, the company attributed the 2025 change to lower cost of sales, reflecting better cost ratios, and lower selling and administrative expenses, including bad-debt and commission costs.

Net loss attributable to controlling shareholders was KRW 3.86 billion in 2024 and KRW 3.3 billion in 2025, a loss in each of the two years, and the net loss including non-controlling interests was reported at the same levels.

At the end of 2025, total equity was KRW 9.22 billion, all attributable to controlling shareholders, and total liabilities were KRW 6.27 billion, with the debt ratio easing from 106.4 percent in 2024 to 67.9 percent in 2025.

Operating cash flow was negative in all four years: KRW -1.63 billion in 2022, KRW -4.03 billion in 2023, KRW -2.11 billion in 2024 and KRW -3.35 billion in 2025.

Quarterly sales were KRW 1.06 billion in Q3 2025, KRW 767 million in Q4 2025 (down 27.7 percent quarter on quarter), KRW 464 million in Q1 2026 (down 39.5 percent), KRW 1.17 billion in Q2 2026 (up 151.8 percent) and KRW 447 million in Q3 2026 (down 61.7 percent, and down 57.8 percent year on year).

Q3 2026 operating loss was KRW 1.03 billion, a wider loss than the prior quarter. Because fiscal 2025 received a disclaimer of opinion over a limit on audit scope, these figures should be read with that limit on verification in mind.

05

Industry analysis

Mass-spectrometry-based microbial identification is used in hospital labs to identify bacteria, and Asta's medical sales fall in this category.

WiseReport's earnings commentary, as of September 6, 2026, cited overseas expansion of medical MALDI-TOF and higher supply of industrial LDI-TOF instruments as drivers of first-half sales growth.

The same source said MALDI-TOF applications are widening beyond microbial identification into food safety, environmental and pharmaceutical fields.

For the sector as a whole, a MediPana News headline reported that 29 in vitro diagnostics companies saw first-half 2026 sales rise 7 percent and operating losses improve 23 percent.

That is an industry aggregate and does not match Asta's own direction, since its first-half 2026 standalone operating loss widened 22.2 percent. Industrially, Asta's instruments are used for display and OLED process analysis, so it serves both medical and industrial demand.

Instrument sales tend to move with hospital replacement and expansion cycles and with overseas approval timing, which is consistent with the swing in quarterly sales to KRW 1.17 billion in Q2 2026 and KRW 447 million in Q3 2026.

In competition, domestic and foreign diagnostics and mass spectrometry makers compete for the same hospital testing demand. Revenue tends to stabilize as consumables and service income grow on an installed base, and Asta's service and other revenue is 95.12 percent domestic.

06

Outlook

The company's stated plans fall into three areas. The first is wider overseas sales of medical MALDI-TOF systems, including Middle East entry through a Saudi joint venture.

The second is supply of industrial LDI-TOF instruments and technology licensing, where WiseReport data as of September 6, 2026 show investment rising and the operating loss widening. The third is a cloud platform for medical and industrial use built on the company's accumulated technology.

On the near-term contract side, the April 2026 supply deal with Kangwon National University (KRW 401 million, with a term ending August 19, 2026) was disclosed. On the audit side, the contract with the external auditor for the 21st fiscal year was disclosed on August 12, 2026.

The review opinion on standalone financial statements in the half-year report filed on August 14, 2026 was also a disclaimer, citing a limit on review scope.

The exchange's improvement period runs to April 10, 2027, and within 15 business days after it ends the company must submit an implementation report and an expert confirmation. The dates could change if an extension of the business report filing deadline is filed.

On governance, the share transfer agreement signed on February 10, 2026 was released on October 16, 2026. A July 2026 news report said the prospective acquirer intended to keep its plan, which differs from the October disclosure.

The next checkpoints are therefore the audit outcome in the 2026 business report and any follow-up disclosures on the largest shareholder.

07

Valuation

PER
—
PBR
—
ROE
-38.5%
EPS
-₩292
BPS
—
Dividend per share
₩0

Valuation is better read through assets and cash flow than through earnings at this stage. Because the company has posted net losses over the last four quarters, no earnings-based multiple can be calculated.

No dividend is being paid, and given the operating loss structure and the size of equity, dividend capacity is limited. Market capitalization is well above total equity at the end of 2025, so the stock trades at a large premium to net asset value.

That premium may reflect market expectations for overseas sales and technology businesses, but there are not yet earnings that confirm them. Trading has been suspended since March 24, 2026, which limits how quickly the market price can reflect operating changes.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Overseas sales and industrial supply growth

WiseReport data as of September 6, 2026 show first-half 2026 standalone sales up 113.0 percent, which the company attributes to overseas expansion of medical MALDI-TOF and more industrial LDI-TOF supply.

A KRW 401 million mass spectrometer supply contract with Kangwon National University was also disclosed in April 2026. Applications of MALDI-TOF into food safety, environmental and pharmaceutical fields are cited as an additional demand base.

A trend of narrowing losses

The operating loss narrowed from KRW 2.78 billion in 2022 to KRW 2.59 billion in 2025, and the operating margin improved from -119.8 percent in 2024 to -99.8 percent in 2025. The company cited lower cost of sales from better cost ratios and lower selling and administrative expenses as drivers. The loss narrowing in 2025 even as sales fell can be read as evidence of partial cost-structure improvement.

Technology assets and new business options

The company's database of more than 5,000 bacterial species and its consumables and service-based revenue are cited as technology assets. Asta says it is pursuing Middle East entry through a Saudi joint venture, technology licensing and a cloud platform.

A demo supply of diagnostic equipment to a Saudi medical research institute was disclosed on September 30, 2025.

09

Bear factors

Audit disclaimer and trading halt

A disclaimer of opinion over a limit on audit scope for fiscal 2025 created a delisting ground on March 24, 2026, and trading has been halted since that day. The exchange disclosed an improvement period ending April 10, 2027, and any delisting decision follows its end.

The first-half 2026 review opinion on standalone statements was also a disclaimer citing a limit on review scope.

Quarterly sales swings and continued losses

Operating losses have run for five consecutive quarters from Q3 2025 to Q3 2026, and net losses attributable to controlling shareholders total KRW 4.6 billion over the last four quarters. Q3 2026 sales were KRW 447 million, down 57.8 percent year on year, and the operating loss widened to KRW 1.03 billion. Net loss attributable to controlling shareholders in the same quarter was KRW 1.21 billion.

Governance and financial burden

The share transfer agreement for a change of largest shareholder, signed on February 10, 2026 with a contract value of KRW 32.8 billion, was released on October 16, 2026 after the buyer notified termination.

At the end of 2025, total equity was KRW 9.22 billion and total liabilities KRW 6.27 billion, and the debt ratio eased from 106.4 percent in 2024 to 67.9 percent in 2025. Operating cash flow remained negative at KRW -3.35 billion in 2025.

10

Risk factors

Listing and audit risk

The audit disclaimer has become a delisting ground, and the delisting decision follows the end of the improvement period. The schedule could shift with an extension of the business report filing deadline or an exemption from sanctions for late filing.

The first-half 2026 review carried a disclaimer on the same ground, so the audit result in the next annual report is a key variable.

Governance and funding risk

With the share transfer contract released, the direction of management control is again unclear. Operating cash outflows in all four years from 2022 to 2025, against total equity of KRW 9.22 billion and liabilities of KRW 6.27 billion, leave funding as an open issue.

The gap between the July 2026 report that the acquirer would keep its plan and the October 2026 release disclosure is a point for follow-up disclosures to resolve.

Business and profitability risk

Q3 2026 sales fell to KRW 447 million, and first-half 2026 standalone operating loss widened 22.2 percent as joint venture and technology licensing spending rose, per WiseReport. Because revenue depends on instrument and supply contracts, quarterly results are volatile. At a 2025 operating margin of -99.8 percent, the pace of loss improvement depends on how far sales recover.

11

What to watch next

  1. December 31, 2026

    The end of fiscal 2026. The next financial results to check are in the 2026 business report, which covers Q4 2026, while the latest disclosed quarter is Q3 2026.

  2. March 31, 2027

    The statutory filing deadline for the 2026 business report, three months after fiscal year-end. Because the 2025 audit ended in a disclaimer, the 2026 audit opinion and whether the report is filed on time are the first hurdles for lifting the trading halt. An extension filing could change this date.

  3. April 10, 2027

    The improvement period end date disclosed by the exchange. Within 15 business days after it ends, the company must file an implementation report and an expert confirmation, after which a delisting decision follows.

12

Overall view

Asta is a technology company that sells MALDI-TOF-based microbial diagnostic instruments and consumables, and it posted operating losses every year from 2022 through 2025. Even so, the 2025 operating loss narrowed to KRW 2.59 billion from 2024, and the operating margin improved from -119.8 percent to -99.8 percent.

On the other side, operating losses have run for five consecutive quarters through Q3 2026, and Q3 2026 sales fell 57.8 percent year on year.

On the business side, overseas sales and industrial supply growth are the strengths, while the audit disclaimer, the trading halt and the released largest-shareholder contract are the weaknesses.

Trading has been suspended since March 24, 2026, which blocks the route by which the share price would reflect operating changes.

The next checkpoints are the filing and audit result of the 2026 business report, the exchange's decision around the April 10, 2027 end of the improvement period, and follow-up disclosures on ownership. This report does not present an investment opinion or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. ssl.pstatic.net
  2. thinkpool.com
  3. comp.wisereport.co.kr
  4. comp.wisereport.co.kr
  5. awakeplus.co.kr
  6. stockanalysis.com
  7. kind.krx.co.kr
  8. comp.wisereport.co.kr
  9. astams.com
  10. kr.investing.com
  11. gukjenews.com
  12. m.news.nate.com
  13. vegannews.co.kr
  14. thevc.kr
  15. astams.com
  16. coindar.org
  17. news.nate.com
  18. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis